Advertisement

Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management

  • Laura Blum
  • Karen Cummings
  • James A. Goulet
  • Aaron M. Perdue
  • Cyril Mauffrey
  • Mark E. HakeEmail author
Original Article • HIP - FRACTURES

Abstract

Osteoporosis is a growing problem that is projected to affect more than 50% of American adults by 2020. Bisphosphonate therapy is currently the primary mode of treating osteoporosis in this population. While bisphosphonate therapy has been successful in increasing bone mineral density, data has shown an increased risk of atypical femur fractures with prolonged therapy. Atypical femur fractures are characterized by low-energy or atraumatic injuries that occur in the subtrochanteric region. They originate on the medial cortex, travel transversely, and typically have little or no comminution. Conservative therapy is indicated for patients with incomplete fractures without prodromal symptoms. Patients with incomplete fractures and significant prodromal symptoms or visible fracture line on radiographs, those who have failed conservative management, and those with complete fractures should be treated with intramedullary nail fixation. Evaluation should involve imaging of the contralateral femur. Teriparatide therapy may be considered for patients without contraindications. While the incidence of these fractures is low, it is likely that these rates will increase with the aging population and increased prevalence of patients being treated with bisphosphonate therapy.

Keywords

Atypical femur fracture Bisphosphonate therapy Stress fractures Osteoporosis 

Notes

Funding

No outside funding was required for this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004. Google Scholar
  2. 2.
    Siris ES, Pasquale MK, Wang Y, Watts NB (2011) Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res 26(1):3–11CrossRefPubMedGoogle Scholar
  3. 3.
    Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA et al (2011) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 26(1):12–18CrossRefPubMedGoogle Scholar
  4. 4.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535–1541CrossRefPubMedGoogle Scholar
  5. 5.
    Feller RJ, Cohen E, Born CT, Hayda R (2015) Atypical fractures of the femur: evaluation and treatment. JBJS Rev 3(3):1–8CrossRefGoogle Scholar
  6. 6.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29(1):1–23Google Scholar
  7. 7.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) American society for bone and mineral research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research. J Bone Miner Res 25(11):2267–2294CrossRefPubMedGoogle Scholar
  8. 8.
    Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D et al (2012) Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 27(5):977–986CrossRefPubMedGoogle Scholar
  9. 9.
    Schilcher J, Aspenberg P (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 80(4):413–415CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lo JC, Huang SY, Lee GA, Khandewal S, Provus J, Ettinger B et al (2012) Clinical correlates of atypical femoral fracture. Bone 51(1):181–184CrossRefPubMedGoogle Scholar
  11. 11.
    Bogdan Y, Tornetta P, Einhorn TA, Guy P, Leveille L, Robinson J, Bosse MJ, Haines N, Horwitz D, Jones C, Schemitsch E, Sagi C, Thomas B, Stahl D, Ricci W, Brady M, Sanders D, Kain M, Higgins TF, Collinge C, Kottmeier S, Friess D (2015) Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort. J Orthop Trauma.  2015 Dec 19. [Epub ahead of print]Google Scholar
  12. 12.
    Maratt J, Schilling PL, Holcombe S, Dougherty R, Murphy R, Wang SC, Goulet JA (2014) Variation in the femoral bow: a novel high-throughput analysis of 3922 femurs on cross-sectional imaging. J Orthop Trauma 28(1):6–9CrossRefPubMedGoogle Scholar
  13. 13.
    Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55(2):495–500CrossRefPubMedGoogle Scholar
  14. 14.
    Nachtrab O, Cassar-Pullicino VN, Lalam R, Tins B, Tyrrell PNM, Singh J (2012) Role of MRI in hip fractures, including stress fractures, occult fractures, avulsion fractures. Eur J Radiol 81(12):3813–3823Google Scholar
  15. 15.
    McKenna MJ, van der Kamp S, Heffernan E, Hurson C (2013) Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by Extending Femur Length. J Clin Densitom 16(4):579–583. doi: 10.1016/j.jocd.2013.06.004 CrossRefPubMedGoogle Scholar
  16. 16.
    Probst S, Rakheja R, Stern J (2013) Atypical bisphosphonate-associated subtrochanteric and femoral shaft stress fractures: diagnostic features on bone scan. Clin Nucl Med 38(5):397–399CrossRefPubMedGoogle Scholar
  17. 17.
    Donnelly E, Saleh A, Unnanuntana A, Lane JM (2012) Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care 6(3):348–354CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nardi A, Ventura L, Cozzi L, Tonini G, Zennaro R, Celi M, Ramazzina E (2013) The bone anabolic therapy. Aging Clin Exp Res 25(S1):121–124CrossRefGoogle Scholar
  19. 19.
    Chiang CY, Zebaze RMD, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52(1):360–365CrossRefPubMedGoogle Scholar
  20. 20.
    Dell R, Greene D, Tran D (2012) Stopping bisphosphonate treatment decreases the risk of having a second atypical femur fracture. Read at the annual meeting of the American academy of orthopaedic surgeons, Feb 7–11, San Francisco. Paper 190Google Scholar
  21. 21.
    Giusti A, Hamdy NAT, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 47(2):169–80Google Scholar
  22. 22.
    Fracture T, Trial I, Flex LE, Black DM, Schwartz AV, Ensrud KE et al (2013) Effects of continuing or stopping alendronate after 5 years of treatment. JAMA J Am Med Assoc 296(24):2927–2938Google Scholar
  23. 23.
    Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–1737CrossRefPubMedGoogle Scholar
  24. 24.
    Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM (2012) Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J 8(2):103–110CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Banffy MB, Vrahas MS, Ready JE, Abraham JA (2011) Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 469(7):2028–2034CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG (2012) Bisphosphonate-associated femur fractures have high complication rates with operative fixation trauma. Clin Orthop Relat Res 470(8):2295–2301CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Teo BJX, Koh JSB, Goh SK, Png MA, Chua DTC, Howe TS (2014) Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J 96-B(5):658–664CrossRefGoogle Scholar
  28. 28.
    Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–190CrossRefPubMedGoogle Scholar
  29. 29.
    Egol KA, Park JH, Prensky C, Rosenberg ZS, Peck V, Tejwani NC (2013) Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma 27(6):331–335CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2016

Authors and Affiliations

  • Laura Blum
    • 1
  • Karen Cummings
    • 1
  • James A. Goulet
    • 1
  • Aaron M. Perdue
    • 1
  • Cyril Mauffrey
    • 2
  • Mark E. Hake
    • 1
    Email author
  1. 1.Department of Orthopaedic SurgeryUniversity of MichiganAnn ArborUSA
  2. 2.Department of Orthopaedic SurgeryDenver Health Medical CenterDenverUSA

Personalised recommendations